We are live on ! Find out more
CRNX icon

Crinetics Pharmaceuticals
CRNX

49 hedge funds and large institutions have $463M invested in Crinetics Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 49 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

67.3% more ownership

Funds ownership: 0% → 67.3% (+67%)

Holders
49
Holders Change
+49
Holders Change %
–
% of All Funds
1.12%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
49
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
+$113M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$80.7M
3
PA
Perceptive Advisors
New York
+$76.8M
4
O
OrbiMed
New York
+$56.8M
5
RCM
RA Capital Management
Massachusetts
+$50.5M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$453K +$469K +15,813 New
Deutsche Bank
27
Deutsche Bank
Germany
$451K +$468K +15,760 New
BCM
28
BlueCrest Capital Management
Jersey
$381K +$395K +13,289 New
Morgan Stanley
29
Morgan Stanley
New York
$353K +$366K +12,336 New
LCM
30
Landscape Capital Management
New Jersey
$341K +$353K +11,893 New
TD Asset Management
31
TD Asset Management
Ontario, Canada
$313K +$324K +10,919 New
California State Teachers Retirement System (CalSTRS)
32
California State Teachers Retirement System (CalSTRS)
California
$302K +$313K +10,526 New
ZP
33
Zimmer Partners
New York
$287K +$297K +10,000 New
TCIM
34
TIAA CREF Investment Management
New York
$268K +$278K +9,351 New
TA
35
Teachers Advisors
New York
$260K +$270K +9,080 New
AIG
36
American International Group
New York
$132K +$137K +4,620 New
Wells Fargo
37
Wells Fargo
California
$97K +$101K +3,385 New
Rockefeller Capital Management
38
Rockefeller Capital Management
New York
$91K +$93.9K +3,161 New
Barclays
39
Barclays
United Kingdom
$75K +$77.4K +2,608 New
FIA
40
FNY Investment Advisers
New York
$57K +$59.4K +2,000 New
SO
41
STRS Ohio
Ohio
$57K +$59.4K +2,000 New
Citigroup
42
Citigroup
New York
$56K +$57.8K +1,946 New
UBS Group
43
UBS Group
Switzerland
$47K +$48.6K +1,637 New
JP Morgan Chase
44
JP Morgan Chase
New York
$46K +$47.9K +1,613 New
Bank of America
45
Bank of America
North Carolina
$36K +$36.9K +1,243 New
Legal & General Group
46
Legal & General Group
United Kingdom
$30K +$31.3K +1,053 New
AIP
47
Ameritas Investment Partners
Nebraska
$16K +$17K +574 New
Royal Bank of Canada
48
Royal Bank of Canada
Ontario, Canada
$9K +$9.74K +328 New
Bank of Montreal
49
Bank of Montreal
Ontario, Canada
$1K +$1.43K +48 New
1
2

CRNX Hedge Fund Activity: Q3 2018 in Review

49 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q3 2018, worth a combined $463M.

Buyers outnumbered sellers: 49 funds opened new CRNX positions and 0 closed out — a net gain of 49 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Vivo Capital, opening a new position worth an estimated $113M.

  • 49 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q3 2018, up from 0 in Q2 2018.
  • Funds reported $463M of Crinetics Pharmaceuticals stock for Q3 2018.
  • 49 funds opened new Crinetics Pharmaceuticals positions in Q3 2018 and 0 closed out, a net change of +49 holders.
  • The largest Crinetics Pharmaceuticals buyer in Q3 2018 was Vivo Capital, an estimated $113M added.

Based on aggregated 13F filings for Q3 2018.